Arcus Biosciences, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 136
Rang # Quantité totale PI 9 647
Note d'activité PI 3/5.0    129
Rang # Activité PI 5 350
Symbole boursier RCUS (nyse)
ISIN US03969F1093
Capitalisation 1,600M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Services scientifiques, technolo...

Brevets

Marques

48 5
23 1
57 0
2
 
Dernier brevet 2025 - Salt forms of an axl inhibitor
Premier brevet 2016 - Methods, apparatuses, and system...
Dernière marque 2021 - A
Première marque 2016 - ARCUS BIOSCIENCES

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Salt forms of an axl inhibitor. 2 -Naphthalene sulfonate salt forms of Compound (I), compositions...
Invention Thiazole compounds and methods of use thereof. The present disclosure is directed to compounds h...
Invention Thiazole compounds as kit inhibitors and methods of use thereof. The present disclosure is direct...
Invention Cbl-b inhibitors and methods of use thereof. Disclosed herein are compounds that are Cbl-b inhibi...
Invention Kit inhibitor compounds and methods of use thereof. The present disclosure is directed to compoun...
Invention Triazolopyridine compounds as inhibitors of kit. The present disclosure is directed to compounds ...
Invention Tetralins targeting mutant hif-2α. Disclosed herein are compounds or pharmaceutically acceptable ...
Invention Compounds as inhibitors of axl. Compounds of Formula I that inhibit AXL, and compositions contain...
Invention Biomarkers for predicting cancer treatment efficacy. Provided herein are biomarkers useful in the...
Invention Cbl-b inhibitors and methods of use thereof. Disclosed herein are compounds having a structure a...
Invention Cbl-b inhibitors and methods of use thereof. Disclosed herein are compounds having a structure ac...
Invention Cbl-b inhibitors and methods of use thereof. Disclosed herein are compounds that are Cbl-b inhib...
Invention Inhibitors of adenosine 5′-nucleotidase. Compounds that modulate the conversion of AMP to adenosi...
Invention Anti-cd39 antibodies and use thereof. Provided herein are anti-CD39 antibodies that inhibit the ...
2023 Invention Modulators of 5'-nucleotidase, ecto and the use thereof. Compounds that modulate the conversion ...
Invention Processes for preparing azolopyrimidine compounds. Disclosed are processes for preparing azolopyr...
Invention Lyophilized formulations of cd73 compounds. Lyophilized formulations comprising a compound of Fo...
Invention Lyophilized formulations of cd73 compounds. Lyophilized formulations comprising a compound of For...
Invention Antibodies to tigit. The present disclosure provides antibodies that specifically bind to TIGIT....
Invention Hpk1 inhibitors and methods of use thereof. Disclosed herein are compounds that are Hematopoietic...
Invention Dispersions of etrumadenant
Invention Dispersions of etrumadenant. Solid dispersion comprising 20-40 wt% of etrumadenant and 60-80 wt% ...
Invention Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha. Compounds that inhibit HI...
Invention Inhibitors of hpk1 and methods of use thereof. Disclosed herein are compounds that are Hematopoi...
Invention Inhibitors of hpk1 and methods of use thereof. Disclosed herein are compounds that are Hematopoie...
Invention Compounds as inhibitors of axl
Invention Compounds as inhibitors of axl. Compounds of Formula I that inhibit AXL, and compositions contai...
Invention Anti-tigit antibodies and uses of the same. Described herein are treatments and preventions for ...
Invention Anti-tigit antibodies and uses of the same
Invention Anti-tigit antibodies and uses of the same. Described herein are treatments and preventions for c...
Invention Combination therapy for treating tumor antigen expressing cancers
Invention Combination therapy for treating trop-2 expressing cancers. e.g.e.g.e.g., etrumadenant, quemliclu...
Invention Combination therapy for treating tumor antigen expressing cancers. The present disclosure relates...
Invention Combination therapy for treating trop-2 expressing cancers
Invention Crystalline forms of a cd73 inhibitor and uses thereof. Crystalline forms of the compound of Form...
Invention Dosing with an azolopyrimidine compound. Provided herein are methods of treating a disease, diso...
Invention Anti-cd39 antibodies and use thereof. Provided herein are anti-CD39 antibodies that inhibit the e...
Invention Anti-cd39 antibodies and use thereof
2022 Invention Inhibitors of hif-2α and methods of use thereof. The present disclosure is directed to compounds ...
Invention Inhibitors of hif-2alpha and methods of use thereof. The present disclosure is directed to compou...
Invention Process for preparing tetralin compounds. The present disclosure describes processes and intermed...
Invention Axl compounds. Compounds of Formula I that inhibit AXL, and compositions containing the compound...
Invention Axl inhibitor compounds. Compounds of Formula I that inhibit AXL, and compositions containing th...
2021 P/S Pharmaceutical and biological drugs for the treatment of a variety of human diseases and disorder...
Invention Oral formulations of cd73 compounds. Oral formulations comprising a compound of Formula (I) and a...
2020 P/S Promoting collaboration within the scientific, research, and medical communities to achieve advan...
2018 P/S Pharmaceutical and/or biological drugs for the treatment of a variety of human diseases and disor...
2017 P/S Research and development services in the field of cancer immunotherapy; conducting clinical trial...